Literature DB >> 22932115

Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.

Marie Matignon1, Thangamani Muthukumar, Surya V Seshan, Manikkam Suthanthiran, Choli Hartono.   

Abstract

BACKGROUND: Identification of risk factors for renal allograft failure after an episode of acute antibody-mediated rejection (AMR) may help the outcome of this difficult-to-treat complication.
METHODS: During December 2003 to February 2011, 833 kidney graft recipients underwent 1120 clinically indicated biopsies at our center. We reviewed the biopsy results and identified 87 biopsy specimens from 87 patients positive for the degradation product of complement component 4 (C4d) and acute AMR. We generated Kaplan-Meier survival curves and performed a multivariable analysis using the Cox proportional hazards regression model to identify risk factors for allograft failure after C4d+ acute AMR.
RESULTS: Among the 87 patients, 26 had a diagnosis of acute AMR according to the Banff '09 classification schema, 29 had acute AMR and chronic active AMR, 18 had acute AMR and acute T-cell mediated rejection (TCMR), and 14 had acute AMR, chronic active AMR, and acute TCMR. Kaplan-Meier survival estimates showed that concurrent acute TCMR (P=0.001, Mantel-Cox log-rank test), concurrent chronic active AMR (P=0.03), and time to biopsy (P=0.04) are associated with graft survival. The Cox proportional hazards regression analysis identified that concurrent acute TCMR (hazard ratio, 2.59 [95% confidence interval, 1.21-5.55]; P=0.01) and estimated glomerular filtration rate (hazard ratio, 0.65 [95% confidence interval, 0.48-0.88]; P=0.01) are independent risk factors for allograft loss. Concurrent chronic active AMR or time to biopsy was not associated with graft failure by the multivariable Cox analysis.
CONCLUSIONS: Our single-center study has elucidated that concurrent acute TCMR in kidney transplant recipients with C4d+ acute AMR is an independent risk factor for graft failure. Level of allograft function at the time of diagnosis was also an independent predictor of graft loss.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22932115      PMCID: PMC3621127          DOI: 10.1097/TP.0b013e31825def05

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  24 in total

1.  Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.

Authors:  H E Feucht; E Felber; M J Gokel; G Hillebrand; U Nattermann; C Brockmeyer; E Held; G Riethmüller; W Land; E Albert
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

2.  Capillary deposition of C4d complement fragment and early renal graft loss.

Authors:  H E Feucht; H Schneeberger; G Hillebrand; K Burkhardt; M Weiss; G Riethmüller; W Land; E Albert
Journal:  Kidney Int       Date:  1993-06       Impact factor: 10.612

3.  The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).

Authors:  A H Tejani; D M Stablein; E K Sullivan; S R Alexander; R N Fine; W E Harmon; E C Kohaut
Journal:  Pediatr Transplant       Date:  1998-11

4.  Effect of histological damage on long-term kidney transplant outcome.

Authors:  B J Nankivell; C A Fenton-Lee; D R Kuypers; E Cheung; R D Allen; P J O'Connell; J R Chapman
Journal:  Transplantation       Date:  2001-02-27       Impact factor: 4.939

5.  A personal perspective: 100-year history of the humoral theory of transplantation.

Authors:  Paul I Terasaki
Journal:  Transplantation       Date:  2012-04-27       Impact factor: 4.939

6.  Rituximab therapy for acute humoral rejection after kidney transplantation.

Authors:  Stanislas Faguer; Nassim Kamar; Céline Guilbeaud-Frugier; Marylise Fort; Anne Modesto; Arnaud Mari; David Ribes; Olivier Cointault; Laurence Lavayssière; Joelle Guitard; Dominique Durand; Lionel Rostaing
Journal:  Transplantation       Date:  2007-05-15       Impact factor: 4.939

7.  Determinants of poor graft outcome in patients with antibody-mediated acute rejection.

Authors:  C Lefaucheur; D Nochy; G S Hill; C Suberbielle-Boissel; C Antoine; D Charron; D Glotz
Journal:  Am J Transplant       Date:  2007-04       Impact factor: 8.086

8.  Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Authors:  Matthew J Everly; Jason J Everly; Brian Susskind; Paul Brailey; Lois J Arend; Rita R Alloway; Prabir Roy-Chaudhury; Amit Govil; Gautham Mogilishetty; Adele H Rike; Michael Cardi; George Wadih; Amit Tevar; E Steve Woodle
Journal:  Transplantation       Date:  2008-12-27       Impact factor: 4.939

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Role of humoral presenitization in human renal transplant rejection.

Authors:  P Gailiunas; M Suthanthiran; G J Busch; C B Carpenter; M R Garovoy
Journal:  Kidney Int       Date:  1980-05       Impact factor: 10.612

View more
  6 in total

1.  Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Authors:  Denis Viglietti; Alexandre Loupy; Olivier Aubert; Oriol Bestard; Jean-Paul Duong Van Huyen; Jean-Luc Taupin; Denis Glotz; Christophe Legendre; Xavier Jouven; Michel Delahousse; Nassim Kamar; Carmen Lefaucheur
Journal:  J Am Soc Nephrol       Date:  2017-12-18       Impact factor: 10.121

2.  Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients.

Authors:  Andrew M South; Lynn Maestretti; Neeraja Kambham; Paul C Grimm; Abanti Chaudhuri
Journal:  Pediatr Transplant       Date:  2017-08-22

Review 3.  Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: interrogation by urinary cell mRNA profiling.

Authors:  Thangamani Muthukumar; John R Lee; Darshana M Dadhania; Ruchuang Ding; Vijay K Sharma; Joseph E Schwartz; Manikkam Suthanthiran
Journal:  Transplant Rev (Orlando)       Date:  2014-05-27       Impact factor: 3.943

4.  High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.

Authors:  Erik Stites; Dhiren Kumar; Oyedolamu Olaitan; Sidney John Swanson; Nicolae Leca; Matthew Weir; Jonathan Bromberg; Joseph Melancon; Irfan Agha; Hasan Fattah; Tarek Alhamad; Yasir Qazi; Alexander Wiseman; Gaurav Gupta
Journal:  Am J Transplant       Date:  2020-03-10       Impact factor: 8.086

5.  Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.

Authors:  Marius Andreas Koslik; Justa Friebus-Kardash; Falko Markus Heinemann; Andreas Kribben; Jan Hinrich Bräsen; Ute Eisenberger
Journal:  Front Med (Lausanne)       Date:  2022-01-31

Review 6.  Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.

Authors:  Carrie A Schinstock; Roslyn B Mannon; Klemens Budde; Anita S Chong; Mark Haas; Stuart Knechtle; Carmen Lefaucheur; Robert A Montgomery; Peter Nickerson; Stefan G Tullius; Curie Ahn; Medhat Askar; Marta Crespo; Steven J Chadban; Sandy Feng; Stanley C Jordan; Kwan Man; Michael Mengel; Randall E Morris; Inish O'Doherty; Binnaz H Ozdemir; Daniel Seron; Anat R Tambur; Kazunari Tanabe; Jean-Luc Taupin; Philip J O'Connell
Journal:  Transplantation       Date:  2020-05       Impact factor: 5.385

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.